SCHEDULE 13G: Andera Partners and Affiliates Disclose 6.5% Stake in Inventiva S.A.

Andera Partners, BioDiscovery 6 FPCI, and their managing partners have jointly disclosed a beneficial ownership of 6.5% of Inventiva S.A.'s ordinary shares.

Summary

• Andera Partners, BioDiscovery 6 FPCI, Stephane Bergez, and Francois Xavier Mauron have filed a Schedule 13G, reporting their beneficial ownership in Inventiva S.A.
• The reporting persons collectively beneficially own 6,148,147 ordinary shares of Inventiva S.A.
• This ownership represents 6.5% of Inventiva S.A.'s outstanding ordinary shares.
• The percentage is based on 94,949,759 ordinary shares outstanding as of December 19, 2024, as reported by Inventiva S.A. in a Form 6-K filing.
• BioDiscovery 6 FPCI is the record holder of the shares, with voting and dispositive decisions made by its management company, Andera Partners.
• Stephane Bergez and Francois Xavier Mauron are the managing partners of Andera Partners, and thus are deemed to beneficially own the securities.
• The reporting persons explicitly disclaim status as a 'group' for the purposes of this Schedule 13G and state the securities were not acquired to change or influence control of the issuer.

Sentiment

Score: 7

Explanation: The disclosure of a significant beneficial ownership stake by a reputable investment firm is generally viewed positively as it signals confidence in the company. While a 13G is a factual disclosure, the act of taking a substantial position implies a positive outlook from the investor's perspective.

Positives

• Disclosure of a significant stake by an investment firm and its affiliates may signal confidence in Inventiva S.A.'s long-term prospects.
• Increased transparency regarding major shareholders provides clarity for other investors.

Risks

• The reporting persons explicitly disclaim forming a 'group' and state their acquisition is not for the purpose of changing or influencing control, which could limit their active engagement in corporate governance beyond standard shareholder rights.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Inventiva S.A.'s future performance or operations.

Management Comments

• "The Reporting Persons expressly disclaim status as a 'group' for purposes of this Schedule 13G."
• "[The] securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing indicates a significant investment by a French private equity firm specializing in life sciences (Andera Partners, via BioDiscovery 6 FPCI) into Inventiva S.A., a biotechnology company. Such investments are common in the biotech sector, where specialized funds provide capital and often take significant stakes in promising companies.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, potentially influencing market perception and liquidity.
• Management: Awareness of a substantial shareholder, though the filing disclaims intent to influence control.

Key Dates

Keywords

Inventiva S.A., Andera Partners, BioDiscovery 6 FPCI, Schedule 13G, Beneficial Ownership, Ordinary Shares, Biotechnology, Pharmaceuticals, Investment, Shareholder, SEC Filing